Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B)

Vaccine

Volumn 28, Issue 45, 2010, Pages 7313-7318

  Shearer, Jeffry D ^a   Vassar, Michelle L ^b   Swiderski, William ^a   Metcalfe, Karen ^a   Niemuth, Nancy ^b   Henderson, Ian ^a  

^a A CSC Company   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Botulinum neurotoxin; Neutralizing antibody; Vaccine

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; IMMUNOGLOBULIN ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT BOTULINUM VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BOTULISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL GUINEA PIG; HUMAN; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTECTION; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; BACTERIAL VACCINES; BOTULINUM TOXINS, TYPE A; GUINEA PIGS; HUMANS; IMMUNIZATION, PASSIVE; MALE; MICE; MICE, INBRED ICR; NEUTRALIZATION TESTS; VACCINES, SYNTHETIC;

EID: 77957752731     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.076     Document Type: Article

References (29)

1. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004, 44:167-193.
2. Sobel J. Botulism. Clin Infect Dis 2005, 41:1167-1173.
3. Sobel J., Tucker N., Sulka A., McLaughlin J., Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 2004, 10:1606-1611.
4. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
5. Centers for Disease Control, Emergency Preparedness and Response Bioterrorism. ; 2010. http://www.bt.cdc.gov/agent/agentlist-category.asp.
6. Dembek ZF, Smith LA, Rusnak JM. Botulinum toxin. In: Dembek ZF, editors, Medical aspects of biological warfare, rev ed. Washington, DC/Falls Church, VA: Office of the Surgeon General United States Army/Borden Institute, Walter Reed Medical Center; 2007. p. 337-53.
7. Arnon S.S., Schechter R., Maslanka S.E., Jewell N.P., Hatheway C.L. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006, 354(5):462-471.
8. Franz D.R., Pitt L.M., Clayton M.A., Hanes M.A., Rose K.J. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects, 1993, 473-477. Plenum Press, New York, NY. B.R. Das Gupta (Ed.).
9. Cheng L.W., Stanker L.H., Henderson T.D., Lou J., Marks J.D. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 2009, 77(10):4305-4313.
10. Keller J.E. Characterization of new formalin-detoxified botulinum neurotoxin toxoids. Clin Vac Immunol 2008, 15(9):1374-1379.
11. Smith L.A., Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 2007, 27:303-318.
12. Smith L.A. Botulism and vaccines for its prevention. Vaccine 2009, 27:D33-D39.
13. Fiock M.A., Cardella M.A., Gearinger N.F. Studies on immunity to toxins of Clostridium botulinum. IX. Immunological response of man to purified pentavalent ABCDE botulinum toxoid. J Immunol 1963, 90:697-702.
14. Siegel L.S. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol 1988, 26:2351-2356.
15. Gelzleichter T.R., Myers M.A., Menton R.G., Niemuth N.A., Matthews M.C., Langford M.J. Protection against botulinum toxins provided by passive immunization with botulinum human immune globul: evaluation using an inhalation model. J Appl Toxicol 1999, 19. S35-S3.
16. Byrne M., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82:955-966.
17. Ravichandran E., Gong Y., Al Saleem F.H., Ancharski D.M., Joshi S.G., Simpson L.L. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 2006, 318(3):1343-1351.
18. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., Gong Y., Simpson L.L. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007, 75(6):3043-3054.
19. Al-Saleem F.H., Ancharski D.M., Ravichandran E., Joshi S.G., Singh A.K., Gong Y., Simpson L.L. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther 2008, 326(3):856-863.
20. Sepulveda J., Mukherjee J., Tzipori S., Simpson L.L., Shoemaker C.B. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun 2010, 78(2):756-763.
21. Cardella M.A. Botulinum toxoids. Botulism: Proceeding of a Symposium 1964, 113-130. K.H. Lewis, K. Cassel (Eds.).
22. Bowmer E.J. Preparation and assay of the international standards for Clostridium botulinum types A, B, C, D and E antitoxins. Bull World Health Organ 1963, 29:701-709.
23. Finney D.J. Probit analysis 1971, Cambridge University Press, Cambridge, England. third ed.
24. Iakovlev A.M. Significance of antitoxic immunity in protection of the organism in respiratory penetration of bacterial toxins. I. Role of passive immunity in protection of the organism from respiratory lesions by B. botulinus toxins. Zh Mikrobiol Epidemiol Immunobiol 1958, 29(6):63-68.
25. Oberst F.W., Crook J.W., Cresthull P., House M.J. Evaluation of botulinum antitoxin supportive therapy and artificial respiration in monkeys with experimental botulism. Clin Pharm Ther 1967, 9:209-214.
26. Lewis G.E., Metzger J.F. Studies on the prophylaxis and treatment of botulism. Natural toxins 1980, 601-606. Pergamon Press, Oxford. D. Eaketr, T. Wadstrom (Eds.).
27. Golub E.S. The cellular basis of the immune response 1981, Sinauer Associates Inc, Sunderland, MA. second ed.
28. Hill K.K., Smith T.J., Helma C.H., Ticknor L.O., Foley B.T., Svensson R.T., et al. Genetic diversity among botulinum neurotoxin- producing clostridial strains. J Bacteriol 2007, 189:818-832.
29. Marks J.D. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Movement Disorders 2004, 19(Suppl 8):S101-S108.